Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 51.1%

Neg 0% Neu 0% Pos 51.1%

Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.